Entrada Therapeutics, Inc. (TRDA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.13-0.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TRDA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete and report data from the Cohort 1 open-label period and Cohort 2 multiple ascending dose study of ENTR-601-44 by the end of 2026.
Stated as a priority in 2 of last 2 quarters. Management reiterated on 2026-Q1 and 2026-Q2 that they are on track to report Cohort 1 open-label and Cohort 2 MAD data by year-end 2026. This aligns with the clinical development timeline and no delays were indicated, showing delivery on this milestone.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“On track to report data from the Cohort 1 open-label period and Cohort 2 MAD by year-end 2026.”
“Company is on track to report data from the Cohort 1 open-label period and Cohort 2 by year-end 2026.”
Ensure sufficient cash, cash equivalents and marketable securities to fund operations through Q3 2027 based on current operating plans.
Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and marketable securities declined from $295.7M at 2025-Q4 to $223.0M at 2026-Q2, yet management consistently affirmed sufficient cash runway into Q3 2027. The trajectory shows ongoing cash use but aligns with the stated runway.
“Cash, cash equivalents and marketable securities sufficient to fund operations into Q3 2027.”
“Cash runway into the third quarter of 2027 with $255 million in cash, cash equivalents and marketable securities.”
“Cash, cash equivalents and marketable securities as of December 31, 2025 sufficient to fund operations into Q3 2027.”
Progress multiple clinical-stage programs targeting DMD including ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51 with data readouts and regulatory filings.
Stated as a priority in 2 of last 2 quarters. Management consistently emphasized advancing multiple DMD clinical programs with ongoing enrollment, dosing, and regulatory filings. While revenue from collaboration declined, clinical progress and data milestones are on track, indicating delivery on this strategic growth priority.
“Advancing multiple clinical programs in people living with Duchenne muscular dystrophy in the U.K., EU and U.S.”
“Advancing multiple clinical programs in people living with Duchenne muscular dystrophy in the U.K., EU and U.S.”
Complete and report data from the ELEVATE-45-201 Cohort 1 multiple ascending dose study by mid-2026.
Stated as a priority in 2 of last 2 quarters. Management reiterated plans to report ELEVATE-45-201 Cohort 1 data in mid to late 2026. The timeline remains consistent with clinical progress and no delays were reported, indicating delivery on this product milestone.
“Company expects to report ELEVATE-45-201 Cohort 1 data in October 2026.”
“On track to report data from ELEVATE-45-201 Cohort 1 in mid-2026.”
The company aims to report results from the Cohort 1 open-label study and Cohort 2 MAD study by the end of 2026.
Over the trailing year it converted 2.55x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.